ADCT Stock Analysis

Adc Therapeutics SA - Real-time stock metrics, market data, and comprehensive analysis

Loading...

Fetching stock data...

Adc Therapeutics SA

ADC Therapeutics is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl). ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. Headquartered in Lausanne (Biopôle), Switzerland, with operations in New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization.

Market Data

Current Price

$1.14

+$0.04 (4.13%)
Market Cap

-

Total Company Value
Day Range
$1.09 - $1.15
Session Volume
542
Shares traded today

Valuation Metrics

P/E Ratio

-

Price ÷ Earnings
EPS (Basic)

-

Earnings Per Share
Price-to-Book

-

Market Value ÷ Book Value

Financial Health

Revenue (TTM)

-

Trailing 12 Months
Net Income (TTM)

-

Profit After Tax
Gross Margin

-

Revenue Efficiency

Returns & Dividends

Dividend Yield

-

Annual Dividend ÷ Price
Annual Dividend

-

Per Share
Payout Ratio

-

Dividend ÷ EPS

Price Performance

Price Chart
All times are in Eastern Time (ET)

Recent News

No news available

Data Source: Financial data is sourced from SEC filings via Tiingo and may be delayed. Market Status: OPEN - Prices update every 2 minutes. (Last updated: 8:54 AM)
Logos provided by Logo.dev

Contact Me

Have a question or want to work together? Fill out the form below and we’ll get back to you as soon as possible.

Contact Form Demo

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.